{"entity":{"id":"mcla-129","kind":"drug","name":"MCLA-129","aka":["bispecific"],"tldr":"MCLA-129 is an experimental bispecific antibody from Betta Pharmaceuticals in phase 2 trials for non-small-cell lung cancer, head and neck squamous cell carcinoma and colorectal cancer, aimed at EGFR and MET.","summary":"MCLA-129 is a bispecific antibody developed by Betta Pharmaceuticals and Merus. Its targets are EGFR and MET (the sponsor names EGFR x c-Met). The sponsor states: A human bispecific antibody targeting both EGFR and c-Met, simultaneously blocking the signalling pathways of both receptors to inhibit tumour growth and survival. ClinicalTrials.gov describes the intervention as: MCLA-129 is a bispecific antibody that targets both EGFR and c-Met, simultaneously blocking the signaling pathways of both EGFR and c-Met, thereby inhibiting tumour growth and survival. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in non-small-cell lung cancer, head and neck squamous cell carcinoma, colorectal cancer, gastric & gastro-oesophageal junction cancer and oesophageal cancer. The largest, NCT04930432, plans to enrol 400 participants with primary completion expected 2028-04-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of MCLA-129","url":"https://clinicaltrials.gov/search?intr=MCLA-129"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","head-and-neck","colorectal","gastric","esophageal"],"sections":[],"technologies":[],"targets":["egfr","met"],"drugs":[],"companies":["betta","genmab"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04930432","nct04868877","nct07448116","nct07208149"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"bispecific antibody","mechanism":"A human bispecific antibody targeting both EGFR and c-Met, simultaneously blocking the signalling pathways of both receptors to inhibit tumour growth and survival.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mcla-129/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}],"company":[{"id":"betta","kind":"company","name":"Betta Pharmaceuticals","route":"/companies/betta/"},{"id":"genmab","kind":"company","name":"Genmab","route":"/companies/genmab/"}],"trial":[{"id":"nct07208149","kind":"trial","name":"A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)","route":"/trials/nct07208149/"},{"id":"nct04868877","kind":"trial","name":"Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combina","route":"/trials/nct04868877/"},{"id":"nct07448116","kind":"trial","name":"Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.","route":"/trials/nct07448116/"},{"id":"nct06885840","kind":"trial","name":"Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.","route":"/trials/nct06885840/"},{"id":"nct04930432","kind":"trial","name":"Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors","route":"/trials/nct04930432/"}],"paper":[{"id":"paper-monumental-1-talquetamab-nejm-2022","kind":"paper","name":"MonumenTAL-1: talquetamab, a GPRC5D-directed bispecific antibody for relapsed multiple myeloma","route":"/key-papers/paper-monumental-1-talquetamab-nejm-2022/"}]}}